Get the Stockscreener App
1.17
1.74%
0.02
After Hours:
1.16
-0.01
-0.85%
Cocrystal Pharma Inc stock is traded at $1.17, with a volume of 13,355.
It is up +1.74% in the last 24 hours and up +3.54% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
See More
Previous Close:
$1.15
Open:
$1.1801
24h Volume:
13,355
Relative Volume:
0.24
Market Cap:
$22.54M
Revenue:
-
Net Income/Loss:
$-8.83M
P/E Ratio:
-1.6001
EPS:
-0.7312
Net Cash Flow:
$-8.01M
1W Performance:
-3.31%
1M Performance:
+3.54%
6M Performance:
+8.33%
1Y Performance:
-6.40%
1-Day Range:
$1.142
$1.1801
1-Week Range:
$1.13
$1.28
52-Week Range:
$0.76
$2.0299
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.17 | 22.54M | 0 | -8.83M | -8.01M | -0.7312 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Cocrystal Pharma, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (COCP) - Traders Union
Cocrystal Pharma’s new CEO hopes to crack the norovirus code - pharmavoice.com
Cocrystal Pharma (COCP) Jumps 8.47% to $1.28 as Biotech Stock Approaches ResistanceHigh Yield Stocks - dars.gov.et
Cocrystal Pharma Completes Dosing in Norovirus Phase 1b Study - TipRanks
Cocrystal Pharma (COCP) Advances Norovirus Antiviral Study Amid High Price-to-Sales Valuation - GuruFocus
Cocrystal Pharma (COCP) finishes dosing human norovirus study, eyes first efficacy readout next - Stock Titan
Cocrystal completes dosing in norovirus drug trial By Investing.com - Investing.com India
No serious adverse events reported as a norovirus drug study reaches final dosing - Stock Titan
Cocrystal completes dosing in norovirus drug trial - Investing.com
symbol__ Stock Quote Price and Forecast - cnn.com
Cocrystal Pharma Inc. (COCP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cocrystal Pharma Inc (COCP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cocrystal Pharma: The Strategic Reset Investors May Be Missing - Yahoo Finance
Cocrystal Pharma (COCP) Climbs 5.45% as Biotech Sentiment ImprovesTriple EMA - dars.gov.et
Cocrystal (COCP) Earnings Snapshot: The Available Earnings Metric Delivers a Miss on the Day; Market Response: Shares Finish 1.71% Down in Latest TradingEarnings Trend Analysis - careplusvn.com
Cocrystal (COCP) director Brosgart files with zero reported holdings - Stock Titan
COCP: 5 Million Private Placement with OPKO Health - Smartkarma
Cocrystal (COCP) Q1 2026 Results: The EPS Result Is Below Expectation in the Reported Period; After Earnings: The Share Price Adds 0.87%Dividend Increase Stocks - vinanet.vn
Stock Options: Choosing The Right Viral Inoculum For An Early-Phase Norovirus Trial - Clinical Leader
Cocrystal Pharma appoints Carol L. Brosgart to board of directors By Investing.com - Investing.com South Africa
Form 8K Cocrystal Pharma Inc For: 18 August By Investing.com - Investing.com Nigeria
Cocrystal Pharma appoints Carol L. Brosgart to board of directors - Investing.com
Cocrystal Pharma Adds Veteran Leader to Board of Directors - TipRanks
Cocrystal Pharma (NASDAQ: COCP) names Carol L. Brosgart to its board - Stock Titan
Cocrystal Pharma strengthens board with antiviral expert appointment - TipRanks
Cocrystal Pharma appoints Carol Brosgart to board to bolster antiviral development - TradingView
Cocrystal Pharma (COCP) appoints antiviral veteran to board - Stock Titan
Cocrystal Pharma Appoints Antiviral Drug Expert Carol Brosgart to Board - citybiz
Cocrystal Pharma appoints Carol Brosgart to board of directors By Investing.com - Investing.com Nigeria
Cocrystal Pharma appoints Carol Brosgart to board of directors - Investing.com
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - The Manila Times
Cocrystal Pharma Appoints Carol Brosgart, M.D. to Board of Directors - Quiver Quantitative
A Gilead veteran joins Cocrystal’s board to guide antiviral drug development - Stock Titan
Cocrystal Pharma Q2 Results: EPS Loss Widens to $(0.23), Misses Estimate - scanx.trade
Cocrystal Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cocrystal Pharma (COCP) flags going-concern risk amid Q2 2026 loss and $5M raise - Stock Titan
Cocrystal Pharma’s single oral drug for multiple viruses - drugdiscoverytrends.com
Cocrystal Pharma Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cocrystal Pharma Inc (COCP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cocrystal Pharma (COCP) adds OPKO and insiders as major holders - Stock Titan
Cocrystal Pharma director Phillip Frost buys $9,816 in stock By Investing.com - Investing.com South Africa
Phillip Frost details 13.9% Cocrystal Pharma (COCP) stake in update - Stock Titan
Cocrystal Pharma director Phillip Frost buys $9,816 in stock - Investing.com
Cocrystal Pharma (COCP) insider buys 10,000 shares via trust - Stock Titan
Cocrystal Pharma, Inc. (COCP) insider-linked trust purchases 75,000 shares - Stock Titan
OPKO Health invests $5 million in Cocrystal Pharma By Investing.com - Investing.com
OPKO Health Boosts Stake in Cocrystal Pharma Financing - TipRanks
Cocrystal Pharma Raises $5 Million in Private Placement With OPKO Health at $0.9134/Share - TradingView
Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health - Stock Titan
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - globenewswire.com
OPKO Buys 5.47M Cocrystal Shares Ahead of Late-2026 Norovirus Data - Stock Titan
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):